Development and Evaluation of Hydralazine Hcl Drug Loaded Solid Lipid Nanoparticles

Abstract

Objective The major goal of the current study was to create and assess solid lipids nanoparticles of Hydralazine hydrochloride to improve its bioavailability.Methodology Solid lipid nanoparticles SLN have recently received a lot of media interest.. Researchers are interested in it because of its increased stability and lower toxicity. Thermal homogenization of hydralazine chlorhydrate and various lipids resulted in the formation of solid lipid nanoparticles. Tristearin Glycerol mono stearate and Compritol 888 were the lipids used soy lecithin was utilized as a surfactant amp stabilizer and tween 80 poloxamer-188 were used for regulated release. Drug release and properties followed a diffusion-controlled release pattern.Results Particle size and PDI polydispersity index zeta potential entrapment efficiency and in vitro drug release were all tested for the nanoparticles. The particle sizes varied between 45.72 and 576.4 nm. All the formulations had good PDI values ranging from 0.119 to 0.411. Blank SLN had a zeta potential of -15.2 mV but drug-loaded SLN had a zeta potential ranging from -12.3 to -32.3 mV. The measured entrapment efficiency was in the range of 78.68 to 96.25.Conclusion The cumulative percentage release of Hydralazine Hcl from different Hydralazine Hcl nanoparticles varied from 53.38 to 89.74 depending on the drug lipid ratio and the type of lipid used. The average percentage of drug released from different SLNs after 24 hours was in the following order F9 53.95 lt F6 56.75 lt F4 61.74 lt F7 63.90 lt F5 67.78 lt F8 69.09 lt F3 75.31 lt F1 79.36 lt F2 89.74. The release kinetic studies showed that the release was first order diffusion controlled and the n values obtained from the Korsmeyer-Peppas model revealed the release mechanism was Quasi-Fickian type n-value of 0.47.